Home > GBL & 1,4-BD: Assessment of risk to the individual and communities in the UK.

Advisory Council on the Misuse of Drugs. [Home Office UK] (2008) GBL & 1,4-BD: Assessment of risk to the individual and communities in the UK. London: Home Office. 44 p.

[img]
Preview
PDF (Gamma-butyrolactone (GBL) report) - Published Version
240kB

Gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) are precursor chemicals that are rapidly converted (half-life approximately 1min) to the intoxicant gamma-hydroxybutyrate (GHB) when ingested into the human body.

GHB occurs naturally in small amounts in the brain, and is recognised by specific receptors. It may be an inhibitory neuromodulator, involved among other things in the control of glucose metabolism, oxygen consumption and temperature regulation.


Item Type:Evidence resource
Publication Type:Report
Drug Type:New psychoactive substance, CNS depressants
Intervention Type:AOD disorder harm reduction
Source:Home Office UK
Date:2008
Pages:44 p.
Publisher:Home Office
Corporate Creators:Advisory Council on the Misuse of Drugs
Place of Publication:London
EndNote:View
Accession Number:HRB (Electronic Only)
Related URLs:
Subjects:J Health care, prevention and rehabilitation > Health care administration > Health care quality control
VA Geographic area > Europe > United Kingdom
J Health care, prevention and rehabilitation > Risk and needs assessment > Risk assessment
B Drugs and alcohol substances > Sedatives or tranquillisers (CNS depressants)
L Social psychology and related concepts > Legal availability or accessibility
A Drugs and alcohol use, abuse, and dependence > Drugs and alcohol effects and consequences

Repository Staff Only: item control page